BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200924
DTEND;VALUE=DATE:20200925
DTSTAMP:20260515T042424
CREATED:20200716T140226Z
LAST-MODIFIED:20200716T140226Z
UID:26355-1600905600-1600991999@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Consortium
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly\, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-consortium-1/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200928
DTEND;VALUE=DATE:20200930
DTSTAMP:20260515T042424
CREATED:20200217T113517Z
LAST-MODIFIED:20200817T084802Z
UID:24213-1601251200-1601423999@www.pharmajournalist.com
SUMMARY:2nd European Protein Degradation Congress
DESCRIPTION:With deals in the protein degradation market reaching nearly $2 billion and unique degradation ideas coming into play such as LYTACs and ENDTACs\, eyes are focused on how much further protein degradation-based therapeutics will continue to grow within the pharmaceutical industry. \nFollowing huge success in May 2019\, the 2nd European Protein Degradation Congress\, returns on 28th – 29th September 2020\, where you can hear the most up to date and relevant information for the broad range of topics in the field of targeted protein degradation. \n \nNew areas will cover novel methods in harnessing E3 ligases and the latest discoveries from PROTACs and molecular glues with preclinical and clinical data being shown. \nLeading industry players from biotechs and big pharma will come together to exchange thoughts on how to best overcome obstacles to achieving reliable in vitro and in vivo data. Academic experts will be present their latest research to help build a deeper understanding of the mechanisms involved in the Ubiquitin pathway\, providing a clearer picture on what makes a good\, or not good\, target for degradation. \nTo know more about 2nd European Protein Degradation Congress please click here.
URL:https://www.pharmajournalist.com/event/2nd-european-protein-degradation-congress/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200930
DTEND;VALUE=DATE:20201001
DTSTAMP:20260515T042424
CREATED:20200715T141216Z
LAST-MODIFIED:20200715T141216Z
UID:26338-1601424000-1601510399@www.pharmajournalist.com
SUMMARY:Gene Therapy for Inherited Metabolic Disorders
DESCRIPTION:The inaugural Gene Therapy for Inherited Metabolic Disorders Summit will put the spotlight on the understanding of topics from the physiopathology of disease through to the nuances of dosing and delivery methods and designing a trial with endpoints and outcome measures that are meaningful both clinically and to patients. \n \nJoin 60+ industry leaders across the metabolic disorders space to overcome the specific delivery and drug development challenges to accelerate the development of more clinically efficacious\, durable and safe gene therapies for metabolic disorders. \nDon’t miss this opportunity to join pioneers from AstraZeneca\, Amicus Therapeutics and Rocket Pharmaceuticals on this journey to revolutionize the treatment of inherited metabolic disorders. \nTo know more about Gene Therapy for Inherited Metabolic Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-inherited-metabolic-disorders/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200930
DTEND;VALUE=DATE:20201001
DTSTAMP:20260515T042424
CREATED:20200720T141737Z
LAST-MODIFIED:20200720T141737Z
UID:26425-1601424000-1601510399@www.pharmajournalist.com
SUMMARY:Gamma Delta T Therapies Summit
DESCRIPTION:Accelerating the Development of Gamma Delta T Therapies in Oncology \nJoin us on Wednesday\, September 30\, to discuss the precise mechanisms of γδT cells\, examine donor selection for allogeneic therapies\, and deliberate the targeting of solid tumours. \nAs we virtually gather world-leading researchers at the Gamma Delta T Therapies Summit\, learn how the industry is effectively manipulating and engineering gamma delta cells with antibody and cell-based approaches for improved safety\, efficacy and manufacturability to bring to market effective Gamma Delta Therapies for patients in need. \nWith a unique opportunity to pose questions to experts and gain fresh insights on such a fast paced and growing field in a live Q&A\, this digital event is not to be missed. \nFind out more about the event and to see participation opportunities: https://ter.li/qk6gc1
URL:https://www.pharmajournalist.com/event/gamma-delta-t-therapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200930
DTEND;VALUE=DATE:20201002
DTSTAMP:20260515T042424
CREATED:20200821T150023Z
LAST-MODIFIED:20200821T150023Z
UID:26815-1601424000-1601596799@www.pharmajournalist.com
SUMMARY:5th Annual PREDiCT: 3D Oncology & Tissue Models
DESCRIPTION:The Digital 5th PREDiCT: 3D Oncology & Tissue Models Summit will return this September\, with defined tracks and a fresh speaker line-up\, bringing together preclinical scientists to discuss adoption and commercialization of 3D models as an integral part of drug development study. \nThis event is completely free for Drug Developers\, Researchers and Academics. To register your complimentary pass\, simply follow this link: www.3d-oncology-tissuemodels.com/take-part/register/. \nThis fully online meeting will feature over 30+ senior Preclinical Scientists from oncology to cardiovascular to musculoskeletal and CNS backgrounds\, to share their latest data and lessons learned from clinically translatable 3D models to disease modeling of mechanisms\, to attempting complex multi-cellular/organ systems to boost our understanding of functionality and physiological relevancy. \nEmbark on the 3D trailblazing community to boost your confidence in 3D models and accelerate bench to bedside drug development to provide a truly safe\, and effective treatment for patients! \nAccess your copy of the Full Event Guide here.
URL:https://www.pharmajournalist.com/event/5th-annual-predict-3d-oncology-tissue-models/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201006
DTEND;VALUE=DATE:20201009
DTSTAMP:20260515T042424
CREATED:20200813T124435Z
LAST-MODIFIED:20200813T124843Z
UID:26694-1601942400-1602201599@www.pharmajournalist.com
SUMMARY:The 5th Computational Drug Discovery & Development (CDD) for Biologics Summit
DESCRIPTION:Built with insights from the likes of AbbVie\, Sanofi\, Amgen and Takeda; CDD for Biologics Summit has been specifically designed to help biopharma companies define strategies to further adapt computational tools\, mitigate data availability issues and address computational-experimental challenges to add immediate value to their biologics pipelines. \nThis dedicated platform will enable you to address key challenges such as those of widespread data sharing\, the experimental constraints of generating enough data and the importance of overcoming data silo-ing with organizations\, as well as exploring new opportunities including a novel\, AI-derived approach\, an automated high-throughput engineering platform\, successfully deploying ML algorithms and more. \nAcross 3 days online\, 24 experts will share in-depth their findings on: \n• Leveraging machine learning and computational programs to discover\, design and develop de novo antibodies\n• Model and design structure-based antibody and T cell receptor recognition\n• Computational design of antibodies against spike epitopes of SARS-CoV-2\n• Plug and play application and advantages of computational design\n• Deep dives into computational modeling of immunogenicity prediction\, validation; and opportunities for data availability and sharing \nJoin a diverse faculty of experts this October for the 5th annual gathering to uncover progress made\, and how we can accelerate the adoption of computational tools in the discovery and development of biologics. \nTo know more about CDD for Biologics Summit please click here.
URL:https://www.pharmajournalist.com/event/the-5th-computational-drug-discovery-development-cdd-for-biologics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201007
DTEND;VALUE=DATE:20201008
DTSTAMP:20260515T042424
CREATED:20200903T084056Z
LAST-MODIFIED:20200903T084056Z
UID:26934-1602028800-1602115199@www.pharmajournalist.com
SUMMARY:Pulsed x-ray technology & smart optics for a total inspection of pre-fillable syringe cannulas and needle shields
DESCRIPTION:HOSTED BY: HEUFT \nLED BY: DAN MCKEE\nGeneral Manager\, HEUFT USA Inc \nDan McKee is the General Manager of HEUFT USA. He has spent 25 years working with high-speed quality control inspection equipment in the packaging industry. In doing so\, he’s become well versed in non-destructive techniques for testing a wide variety of package attributes using technologies as diverse as x-ray imaging\, capacitive gauging\, inductive profiling\, and various vision techniques. His responsibilities have included commissioning inspection devices within a wide variety of production environments\, specifying devices to satisfy customers’ application conditions and working with R&D to customize equipment to conform to his customers’ unique challenges. Dan now leads HEUFT’s sales and service organization for the United States and Canada. \nDan Received his BSEE from the Illinois Institute of Technology in 1993\, and a Master of Engineering Management (MEM) in 2001 from Northwestern University. \n \nLED BY: RONALD TURN\nPharmaceutical Sales Engineer\, HEUFT USA Inc \nRonald Turn joined Heuft USA in 2019 as the Pharmaceutical Sales Representative. Ron has spent the past 10 years in a technical sales roll selling different varieties of Capital Analytical Research Instrumentation to the Pharmaceutical\, Biotech\, Chemistry\, and Life Sciences industries. Ron also has worked for two major Pharmaceutical companies as an Analytical Chemist. With the combination of sales experience and Scientific knowledge\, Ron is responsible for everything related to the Pharmaceutical portfolio offered by Heuft USA. \nRon Received his bachelor’s degree in Chemistry from Western Illinois University in 2008. \nWebniar overview: \nThe pulsed X-ray detection module from HEUFT identifies numerous safety and integrity defects of pre-fillable syringes after the caps have been applied with unrivaled low radiation. The HEUFT Syringer detects non-conformities that would normally be invisible to a camera system such as needle shields (both SNS & RNS) pierced by the hypodermic needle\, deformed cannulas or incorrectly assembled\, defective or leaking luer-lock screw adapters and tamper evident closures of disposable syringes. \nThe compact detection unit can be enhanced with innovative smart optics for detecting needle hooks which complement the unique pulsed X-ray technology for a careful and precise pre-fillable syringe inspection. An intelligent color sensor camera\, developed by HEUFT\, examines the tiny needle tips from above before the protective covers have been added. The special light dispersion of the adaptive LED lighting used for this purpose ensures that even the smallest faults become visible. \nThe HEUFT Syringer is extremely compact and very easy to integrate into packaging machines for such pre-fillable injection instruments.\nDuring this Webinar\, Information will be shared about the Heuft Syringer such as design features\, functionality\, implementation\, and benefits of using the HEUFT Syringer to assure only quality pre-filled syringes reach the market. \nWHO SHOULD ATTEND?  \n\nQuality Managers\nHeads of Quality\nManufacturing/Operations Managers\nHeads of Manufacturing/Operations\nHeads of Fill-Finish\nFill-Finish Manager\nR&D scientists\nFormulation scientists\nCMC regulatory\nPackaging engineers\nEngineers and Managers in Device Development and all other technical functions surrounding syringe systems\nClinical and commercial Drug Product Manufacturing\nFormulation scientists\nLaboratory scientific staff and managers\nParenteral manufacturing staff\nSterility Quality Assurance\nRegulatory affairs scientists\nPharmaceutical packaging component manufacturing staff\n\nFor more information and to register your free place\, visit:\nhttps://www.smi-online.co.uk/pharmaceuticals/webinar/pfs-cannulas-and-shields \nAdditional Contact Information \nJinna Sidhu – Marketing Manager\nPharmaceutical Division – SMi Group Ltd\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/pulsed-x-ray-technology-smart-optics-for-a-total-inspection-of-pre-fillable-syringe-cannulas-and-needle-shields/
LOCATION:Virtual Webinar
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201008
DTEND;VALUE=DATE:20201010
DTSTAMP:20260515T042424
CREATED:20200422T100729Z
LAST-MODIFIED:20200422T100729Z
UID:25164-1602115200-1602287999@www.pharmajournalist.com
SUMMARY:2nd Flow Cytometry Congress
DESCRIPTION:As a vital tool for providing quantifiable data on cell characteristics\, flow cytometry is an integral part of diagnostics and the assessment of therapeutic efficacy. Talks will also explore the application of flow cytometry in disease monitoring and diagnosis\, and approaches to implementation in the clinic. \n \nThe meeting will focus on: \n\nAdvances in flow cell and sheath fluid design.\nThe development of new fluorophores.\nNext-generation detection systems\, and\nAn applications session exploring the analysis of cell surface antigens\, reviewing cell health\, cell sorting techniques and\nThe role of flow cytometry in drug development.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field. \nDelegates will also have access to the co-located Liquid Biopsies Congress and qPCR and Digital PCR Congress. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/2nd-flow-cytometry-congress/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201008
DTEND;VALUE=DATE:20201010
DTSTAMP:20260515T042424
CREATED:20200422T101205Z
LAST-MODIFIED:20200422T101205Z
UID:25169-1602115200-1602287999@www.pharmajournalist.com
SUMMARY:7th QPCR & Digital PCR Congress
DESCRIPTION:qPCR & Digital PCR are the most essential techniques used for quantification of nucleic acid molecules in molecular biology and diagnostics. \nWhere qPCR is considered as a powerful technique that can provide precise and quantitative data reflecting the biology of the tested experimental parameters\, the excellent precision of dPCR supports its application for the detection of rare point mutations and mutations induced by gene editing in a background of wild-type sequences. \n \nAt this congress our expert speaker panel will address these challenges in the form of case studies and interactive sessions. The agenda will focus on the challenges which need to be addressed to successful move forward into clinical studies: \n\nAccuracy\nReproducibility\nAssay optimization\nMultiplexing\nStandardization\nTranslating methods into applications\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field. \nDelegates will also have access to the co-located Flow Cytometry Congress and Liquid Biopsies Congress. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/7th-qpcr-digital-pcr-congress/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201008
DTEND;VALUE=DATE:20201010
DTSTAMP:20260515T042424
CREATED:20200422T101655Z
LAST-MODIFIED:20200422T101655Z
UID:25174-1602115200-1602287999@www.pharmajournalist.com
SUMMARY:2nd Liquid Biopsies Congress
DESCRIPTION:This conference offers experts working in the biopharmaceutical industry as well as academia the opportunity to examine the latest developments in the field with dedicated congress presentations\, panel discussions and roundtables. \n \nThe agenda will explore : \n\nNovel methods\, research techniques\, advances and discoveries in the field.\nResearch applications utilizing technologies such as qPCR\, Digital PCR and NGS.\nThe detection and analysis of on circulating biomarkers such as cell-free DNA\, (cfDNA)\, circulation tumor cells (CTCs)\, and extracellular vesicles (EVs).\nThe growing field of single cell analysis and he use of different fluids for non-invasive testing.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field. \nDelegates will also have access to the co-located Flow Cytometry Congress and qPCR & Digital PCR Congress. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/2nd-liquid-biopsies-congress/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201012
DTEND;VALUE=DATE:20201014
DTSTAMP:20260515T042424
CREATED:20200213T113228Z
LAST-MODIFIED:20200415T082610Z
UID:24131-1602460800-1602633599@www.pharmajournalist.com
SUMMARY:Animal Health Investment USA
DESCRIPTION:Animal Health Investment USA is a premier investment forum showcasing the most exciting partner opportunities in animal health and connecting those businesses together with financial investors and strategic corporate partners. \n \nOnce again\, our forum in Boston will be split into two tracks\, a human biotech and animal health partnering track and an investor track. The first will be looking specifically at maximizing the therapeutic and commercial potential of human technologies and serving unmet medical needs in veterinary health\, the second will be focused on driving investor engagement and showcasing the industry’s most exciting emerging companies. \nWe will include keynote presentations and host C-level panel discussions that address the trends and market dynamics of the animal health industry\, across all species. A key element of the investment forum is the full use of a our 1-on-1 meeting scheduler\, available to all attendees. \nTo know more about Animal Health Investment USA please click here.
URL:https://www.pharmajournalist.com/event/animal-health-investment-usa/
LOCATION:Venue tbc\, Boston\, MA\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201013
DTEND;VALUE=DATE:20201016
DTSTAMP:20260515T042424
CREATED:20200803T085442Z
LAST-MODIFIED:20200803T085442Z
UID:26601-1602547200-1602806399@www.pharmajournalist.com
SUMMARY:3rd Targeted Protein Degradation Summit
DESCRIPTION:Off the back of the newly released first-in-human data utilizing PROTACs\, it is more than ever evident that the field of targeted protein degradation is redefining the therapeutic landscape across the whole of the pharmaceutical industry. Despite the recent success\, significant challenges are continuing to hold back the progress of the discovery and development of safe and effective protein degraders. \nFor the 3rd time\, the TPD Summit is providing you with the leading platform that showcases the latest developments and advancements in the field\, bringing together the leading biopharmaceutical and academic organizations in an intimate networking environment to focus on successfully degrading intracellular & extracellular targets\, improving rational design and accelerating the translation of next generation proteasomal- & autophagy- mediated protein degraders into clinical trials. \nHere is a sneak peak of just some of our 60+ world-class speaker faculty: \n\nJay Bradner\, President\, Novartis Institutes for Biomedical Research\nCraig Crews\, John C. Malone Professor of MCDB\, Chemistry & Pharmacology\, Yale University\nAlessio Ciulli\, Professor of Chemical & Structural Biology\, University of Dundee\nMatt Disney\, Professor of Chemistry & Neuroscience\, Scripps Research\nIan Churcher\, Chief Scientific Officer\, Amphista Therapeutics\nJohn Houston\, President & Chief Executive Officer\, Arvinas\nRay Deshaies\, Senior Vice President of Global Research\, Amgen\nNello Mainolfi\, Founder\, President & Chief Executive Officer\, Kymera Therapeutics\nStewart Fisher\, Chief Scientific Officer\, C4 Therapeutics\nScott Edmondson\, Director & Head of Boston Oncology Chemistry\, AstraZeneca\nYu Shen\, Director of Cancer Biology\, AbbVie\nRichard Glynne\, Chief Scientific Officer\, Lycia Therapeutics\nIngrid Wertz\, Principal Scientist & Project Team Lead\, Genentech\n\nDon’t miss the most comprehensive\, industry-focused meeting in the field specifically dedicated to the discovery and development of targeted protein degradation strategies to advance your pipelines towards success!
URL:https://www.pharmajournalist.com/event/3rd-targeted-protein-degradation-summit/
LOCATION:Digital Event – EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201019
DTEND;VALUE=DATE:20201021
DTSTAMP:20260515T042424
CREATED:20200422T102229Z
LAST-MODIFIED:20200422T102229Z
UID:25178-1603065600-1603238399@www.pharmajournalist.com
SUMMARY:8th Plant Genomics & Gene Editing Congress: USA
DESCRIPTION:The Congress will explore novel strategies and developments in plant genomics and gene editing through a series of case studies and an examination of the latest scientific research. Leaders from academia and industry will consider key developments in gene editing technologies such as CRISPR/Cas9 and TALEN and discuss its application in improving disease resistance\, stress tolerance and crop yield. \n \n\nDiscover how research institutions and agri-biotech are using gene-editing technologies to advance their research.\nLearn how to apply successful bioinformatic strategies to overcome plant phenotyping challenges.\nExplore the impact of gene editing regulation.\nBuilding on existing partnerships and creating new collaborations across industry & academia\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/8th-plant-genomics-gene-editing-congress-usa/
LOCATION:Raleigh-Durham\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201019
DTEND;VALUE=DATE:20201021
DTSTAMP:20260515T042424
CREATED:20200422T102705Z
LAST-MODIFIED:20200422T102705Z
UID:25182-1603065600-1603238399@www.pharmajournalist.com
SUMMARY:5th Partnerships in Biocontrol & Biostimulants Congress: USA
DESCRIPTION:Case studies across the two days will examine developments in biopesticides and biostimulants and the application of new research in increasing crop yield\, improving soil health & nutrient uptake\, and efficient water use. Experts from industry and academia will also discuss pest management strategies and provide regulatory updates in the field. \n \n\nDiscover how research institutions and agri-biotech are developing the next generation of bacterial biostimulants.\nLearn how to apply successful bioinformatic strategies to advance your research.\nExplore the updated understanding of biopesticides and biostimulants regulation.\nHear about insights into the role of plant and soil microbiomes.\nBuild on existing partnerships and create new collaborations across industry & academia.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/5th-partnerships-in-biocontrol-biostimulants-congress-usa/
LOCATION:Raleigh-Durham\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201019
DTEND;VALUE=DATE:20201021
DTSTAMP:20260515T042424
CREATED:20200422T103314Z
LAST-MODIFIED:20200422T103314Z
UID:25186-1603065600-1603238399@www.pharmajournalist.com
SUMMARY:Microbiome for Agriculture Congress: USA
DESCRIPTION:The meeting will examine the symbiotic relationships between microbes and plants through case studies in plant and soil microbiomes. Academic and industry leaders will discuss new research into the rhizosphere\, phyllosphere and endosphere and the application of plant and soil microbiome research in improving disease resistance\, nutrient acquisition and crop yield\, and tolerance to multiple stressors including nematodes\, insects and drought.  \nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships.  \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/microbiome-for-agriculture-congress-usa/
LOCATION:Raleigh-Durham\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201019
DTEND;VALUE=DATE:20201022
DTSTAMP:20260515T042424
CREATED:20200803T090036Z
LAST-MODIFIED:20200813T133334Z
UID:26605-1603065600-1603324799@www.pharmajournalist.com
SUMMARY:5th Microbiome Movement – Drug Development Summit
DESCRIPTION:The 5th Microbiome Movement – Drug Development Summit (October 19-21\, Digital Event – EDT) continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical\, biotech and academic community pursue the causal role of the human microbiome in disease\, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable MoAs. \n \nWith over 60 speakers taking part\, the four focus areas for 2020 include: \n\nPre-Clinical Development & Mechanisms of Microbiome-based Therapeutics\nLearn how industry and academic pioneers are developing novel microbiome platforms to identify new targets and therapeutics across a range of microbiome-targeting modalities and disease phenotypes\nClinical Development\, Manufacturing & Commercialization of Live Biotherapeutics\nAs the industry prepares for pivotal clinical readouts this summer\, this year’s discussion will give you the knowledge and insight required to navigate through the specific translational\, clinical and manufacturing challenges for live biotherapeutics\nMicrobiome-based Biomarkers\, Diagnostics & Patient Stratification\nMine the human microbiome to discover new biomarkers of disease and help predict response\, understand drug metabolism and develop non-invasive diagnostic tools\nApplications in Oncology\nGain a comprehensive insight into the most exciting disease target in microbiome research today with case-studies and discussion from leading cancer researchers\, oncology-specific clinicians and the pharmaceutical industry\n\nIf you are\, or would like to be\, a player in the microbiome arena\, this is the conference you should attend to not only hear the latest pre-clinical and clinical development from organizations developing microbiome-based therapeutics\, biomarkers and diagnostics\, but also to make long-lasting connections that will accelerate your microbiome developments forward\, and help translate this promising science into a reality for patients.
URL:https://www.pharmajournalist.com/event/5th-microbiome-movement-drug-development-summit/
LOCATION:Digital Event – EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201020
DTEND;VALUE=DATE:20201022
DTSTAMP:20260515T042424
CREATED:20200910T130153Z
LAST-MODIFIED:20200917T151939Z
UID:26975-1603152000-1603324799@www.pharmajournalist.com
SUMMARY:Outsourcing in Clinical Trials Nordics 2020
DESCRIPTION:After the challenges of 2020 with the Covid-19 pandemic\, this is the unmissable event that the pharmaceutical\,\nbiotechnology\, and medical device communities need to come together and discuss strategies for operational success in clinical trials. With all the latest content\, and a big focus on the latest regulations and technology\, the conference will offer an unparalleled opportunity to hear in-depth talks from the likes of the Danish Medicines Agency\, LEO Pharma\, and TÜV SÜD\, as well as C-level and senior experts from the Nordic region. \n\nTo know more about Outsourcing in Clinical Trials Nordics 2020 please click here.
URL:https://www.pharmajournalist.com/event/outsourcing-in-clinical-trials-nordics-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Arena International Events Group":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201028
DTSTAMP:20260515T042424
CREATED:20181206T115237Z
LAST-MODIFIED:20200320T123611Z
UID:18694-1603670400-1603843199@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes East Coast 2020
DESCRIPTION:SMi are proud to announce the 7th annual conference: \nPre-Filled Syringes East Coast 2020\n26-27 October 2020\nBoston\, USA\nSheraton Boston Hotel\nhttp://www.pfsamericas.com/pjwl \nInnovations in parenteral device and product development \n \nSMi Group are proud to announce the 7th Pre-Filled Syringes East Coast conference returning to Boston\, USA on 26th-27th October 2020. \nThe global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry\, is expected to exceed $9.7 billion by 2025. With that in mind\, for its 7th year running- the 2020 event will aim to focus on new trends on digital technology advancements\, human studies and innovative design and delivery systems within the prefilled syringe industry. \nThemes for 2020: \nPre-Filled Syringes East Coast 2020 will be exploring themes of Container Closure Interaction and Formulation; On-body Injectors; Digital connectivity in the parenteral space; A regulatory outlook with industry and recognised body experts; Patient centricity and device development; Developments in device technology; Parenteral gene therapy and New for 2020: PFS Interactive Workshop Day. \nThis comprehensive overview will help attendees understand the changing global market and the challenges faced within the industry. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more.. \nKey Reasons to Attend: \n\nEXPLORE the latest case studies parenteral drug delivery\nGAIN insights into the use of pre-filled syringes for gene therapy\nNETWORK with leading industry experts\, key opinion leaders and regulatory body representatives\nENGAGE in the key challenges and topics of the field in the interactive post-conference workshop day\n\nWho should attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers \n\nTo register or for more information visit: www.pfsamericas.com/pjwl \nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #Smipfsusa\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/prefilled-syringes-east-coast/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="SMi Group Ltd":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201029
DTSTAMP:20260515T042424
CREATED:20191215T134154Z
LAST-MODIFIED:20200813T143407Z
UID:23372-1603670400-1603929599@www.pharmajournalist.com
SUMMARY:Smithers’ Extractables and Leachables USA 2020
DESCRIPTION:Smithers’ 9th annual Extractables and Leachables USA conference is returning. This is a unique event in the extractables and leachables industry\, bringing together top companies from the entire supply chain and making it easy to network with peers\, leading to new\, beneficial connections. The event is a must for the extractables and leachables industry\, wherein players need to stay on top of market changes\, fluctuating regulations\, medical device strategies\, and safety standards for consumer safety and product success. Smithers’ E&L 2020 gathers industry experts to discuss these topics\, and more. The program consists of two days of industry-leading presentations by over 20 expert speakers\, supplemented by valuable networking breaks\, an included networking lunch\, and a networking reception at the end of day one. \nCompanies who have attended in the past include B Braun\, The FDA\, Toxikon\, Intertek\, Abbott\, Nelson Laboratories\, Boston Scientific\, Vimta\, Jordi Labs\, VR Analytical\, Teknor Apex\, and many more. \nVisit the event website for more information: https://www.eandl-conference.com/usa. \nContact Producer Ashli Speed\, ASpeed@Smithers.com\, with questions about the program. \nFor companies interested in increasing their brand visibility in front of a target market\, contact Shannon Siegferth\, SSiegferth@Smithers.com\, about sponsorship opportunities. \nTo get the latest updates\, follow the event on twitter @SmithersELEvent\, join the LinkedIn group Extractables and Leachables Forum\, or join the mailing list: https://www.eandl-conference.com/usa/register-interest.
URL:https://www.pharmajournalist.com/event/extractables-and-leachables-usa/
LOCATION:Virtual Event
ORGANIZER;CN="Smithers":MAILTO:sheitzenrater@smithers.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201028
DTSTAMP:20260515T042424
CREATED:20200806T100433Z
LAST-MODIFIED:20200806T100433Z
UID:26627-1603670400-1603843199@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Summit
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Summit will gather the greatest minds in TIGIT research in a dedicated\, two day meeting. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings for your future research. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a meeting that brings together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, this event will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Summit website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-summit/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201029
DTSTAMP:20260515T042424
CREATED:20200817T085404Z
LAST-MODIFIED:20200817T085404Z
UID:26772-1603670400-1603929599@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Rare Disorders Europe | Running Digitally for 2020
DESCRIPTION:Realise the Commercial Potential of Gene Therapies \nThe 4th Annual Gene Therapy for Rare Disorders Europe is dedicated to overcoming\nmanufacturing\, clinical\, and commercialisation challenges drug developers face when delivering\ngene therapies to market. \nWith new European gene therapy approvals rapidly approaching and investment at an all-time high\, the digital meeting will leverage the experience from the first to market pioneers\, as well as unveiling the strategies the next generation of drug developers are employing to improve efficacy\, safety and commercial viability. \n \nAcross three days\, we will virtually unite 250+ leading experts from innovative biotechs\, large pharmaceutical companies\, academia\, and key service providers. Understand the nuances of the European regulatory landscape\, engage with European payers and ensure your manufacturing and logistical approaches are set for the commercial primetime to come. \nWherever you’re based\, if you’re looking to develop and launch gene therapy products in Europe\, this is your comprehensive guide to define your commercial path forward \nTo learn more about Gene Therapy for Rare Disorders Europe please click here: https://ter.li/k19u77
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-rare-disorders-europe-running-digitally-for-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201027
DTEND;VALUE=DATE:20201028
DTSTAMP:20260515T042424
CREATED:20200716T134602Z
LAST-MODIFIED:20200716T135026Z
UID:26349-1603756800-1603843199@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Consortium
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly\, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-consortium-2/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201027
DTEND;VALUE=DATE:20201030
DTSTAMP:20260515T042424
CREATED:20200722T112338Z
LAST-MODIFIED:20200722T112338Z
UID:26438-1603756800-1604015999@www.pharmajournalist.com
SUMMARY:Macrophage-directed Therapies Summit 2020
DESCRIPTION:Harnessing the Potential of Macrophage Therapies Using Small Molecule\, Antibody & Cell Therapy based Approaches for Oncology and Beyond \nWith the explosive excitement and clinical proof of concepts utilizing CD47 approaches\, macrophage-directed therapies have started to witness interest and investment in novel macrophage targets outside of CD47. \n \nThe 2nd Macrophage-directed Therapies Summit is focused on optimizing the potential of macrophage therapies\, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond. \nBringing together the leading experts\, we will explore the clinical development of CD47 checkpoint blockades\, combination strategies\, macrophage repolarization approaches and engineered macrophages. \nJoin the trailblazers of macrophage therapeutic development\, from the likes of Carisma Therapeutics\, Faron Pharmaceuticals\, and Verseau Therapeutic\, as we come together to advance the fundamental understanding of macrophage biology\, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy.
URL:https://www.pharmajournalist.com/event/macrophage-directed-therapies-summit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201028
DTEND;VALUE=DATE:20201030
DTSTAMP:20260515T042424
CREATED:20171009T143124Z
LAST-MODIFIED:20200810T095904Z
UID:3348-1603843200-1604015999@www.pharmajournalist.com
SUMMARY:Pharmaceutical Microbiology East Coast
DESCRIPTION:SMi’s 3rd Annual Pharmaceutical Microbiology East Coast\nConference: 28 – 29 October 2020\nLocation: Virtual Event\nWebsite: www.microbiologyeastcoast.com/PJWL \nSPONSORED BY: Associates of Cape Cod\, bioMérieux\, Bioscience International\, C.T.L. MAT\, LONZA \nCHAIRED BY: Lynne Ensor\,VP Technical\, Parexel \nExploring the current approaches towards improved contamination control \nThe pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods\, revisions being made to regulations in the industry\, enhanced knowledge of the human microbiome\, and novel testing methods\, this industry is ever expanding. \nJoin industry experts to discuss and analyze the latest advances and challenges within the industry. Network with industry professionals\, discuss the revision of Annex 1\, explore data integrity considerations for conventional and rapid microbiology methods\, analyze arising issues with environmental monitoring and gain insight into an industry perspective on automated endotoxin testing and process automation. \nEvent Hashtag: #SMiPharmaMicroEC \nHIGHLIGHTS FOR 2020: \n\nDiscuss ongoing complication of personnel derived contaminations from the FDA\nGain valuable insight towards microbiological quality considerations in non-sterile manufacturing and control of BCC from Parexel\nLearn from the perspective of the US Pharmacopeia on container closure integrity evaluation\nExamine an end-to-end contamination risk assessment for autologous cell therapy from Juno Therapeutics\nExplore a back to back Genentech session covering technical considerations for microbial QC of raw materials used in biotechnology and the past\, current and future state of Mycoplasma testing\n\nThe Use of Recombinant Chromogenic Assays as Alternate Methods for the Bacterial Endotoxins Test (BET) \nWorkshop Leader:\nVeronika Wills\, Manager\, Technical Services\, Associates of Cape Cod \nView the full agenda: www.microbiologyeastcoast.com/PJWL \nWHO SHOULD ATTEND \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist\, Drug Substance External Manufacturer\, QC Scientists\, Heads of Quality\, Business Development Manager\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist \nTo know more about Pharmaceutical Microbiology East Coast please click here.
URL:https://www.pharmajournalist.com/event/pharmaceutical-microbiology-east-coast/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201028
DTEND;VALUE=DATE:20201030
DTSTAMP:20260515T042424
CREATED:20200812T084028Z
LAST-MODIFIED:20200812T084028Z
UID:26683-1603843200-1604015999@www.pharmajournalist.com
SUMMARY:Dry AMD Therapeutic Development Summit
DESCRIPTION:Finding new therapeutics to counter the progression of Dry AMD and prevent the geographical atrophy has never been more important. The aging population creates an ever-growing clinical need for next-generation therapeutics. \nThis action-packed two-day digital agenda holds 22 Presentations from industry and academic leaders\, a virtual poster session and 5+ hours of networking\, you can join the only platform discussing issues present in the development of Dry AMD therapeutics. \n \nJoin this critical global forum which will be uniting industry specialists from pharma\, biotechs\, academia and solution providers as we target the most pressing issues important to bringing the next generation of Dry AMD drugs to market. \nCompanies speaking include: Genentech\, 4D Molecular Therapeutics\, Alkeus Pharmaceuticals\, Inc.\, Boehringer Ingelheim International GmbH\, University of California\, San Francisco\, Regenerative Patch Technologies\, Novartis\, Stealth BioTherapeutics Inc \nFind out more here > https://ter.li/mc1pmz
URL:https://www.pharmajournalist.com/event/dry-amd-therapeutic-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201029
DTEND;VALUE=DATE:20201031
DTSTAMP:20260515T042424
CREATED:20200709T091800Z
LAST-MODIFIED:20200709T092312Z
UID:26239-1603929600-1604102399@www.pharmajournalist.com
SUMMARY:Patient-to-Patient Supply for Cell Immunotherapies Summit
DESCRIPTION:Achieving Standardization & Operational Excellence in Vein-to-Vein Supply \nAs an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment\, cell therapies pose unique supply chain challenges. \n \nAt the inaugural Patient-to-Patient Supply for Cell Immunotherapies Summit\, this community will share their expertise and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale. \nFrom time and temperature sensitivity\, to patient-facing service and integrated platforms\, a seamless vein-to-vein supply chain is central in maintaining cell immunotherapy safety and efficacy at scale and maximizing the patient experience. \nJoin the strategic experts from GSK\, bluebird bio\, Adaptimmune\, Celgene\, BMS and more\, to discuss best practice for patient-facing supply chains and build integrated platforms for chain of identity and end-user access.
URL:https://www.pharmajournalist.com/event/patient-to-patient-supply-for-cell-immunotherapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201103
DTEND;VALUE=DATE:20201106
DTSTAMP:20260515T042424
CREATED:20200803T075703Z
LAST-MODIFIED:20200803T094758Z
UID:26593-1604361600-1604620799@www.pharmajournalist.com
SUMMARY:Digital 5th Neoantigen Based Therapies Summit
DESCRIPTION:With all eyes on the explosive neoantigen field watching to see how it can revolutionize cancer immunotherapies and rival the current T cell therapies\, it is clear that critical questions still remain to be addressed to ensure full therapeutic success. \n \nTaking place from the comfort of your own home this year\, the 5th Neoantigen Based Therapies Summit remains the only industry focused meeting dedicated to the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies. \nView the full event guide for more details on this content packed 3-day virtual event. \nWe’ll be addressing the most pressing challenges in the field\, including: \n\nIdentifying both personalized and shared Neoantigens to supercharge development of next generation immunotherapy with University of Miami and Netherlands Cancer Institute\nImproving prediction accuracy by exploring different neoantigen sources with Ervaxx\, Precision Biologics and Broad Institute\nHow to maximize immunogenicity to drive clinical development & success with Gritstone Oncology\, Genocea and Treos Bio\nReducing complex process and release times by navigating through complex manufacturing challenges with Achilles Therapeutics\, Vaximm and ISA Therapeutics\n\nDownload the official brochure to see what sessions will help you to advance your cancer immunotherapy pipeline. \nJoin us online to gain the practical insights you need to improve the immune response and commercial viability of your neoantigen based cancer immunotherapy.
URL:https://www.pharmajournalist.com/event/digital-5th-neoantigen-based-therapies-summit/
LOCATION:Online | Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201105
DTEND;VALUE=DATE:20201107
DTSTAMP:20260515T042424
CREATED:20200422T104308Z
LAST-MODIFIED:20200605T111205Z
UID:25191-1604534400-1604707199@www.pharmajournalist.com
SUMMARY:8th Microbiome R&D & Business Collaboration Forum: USA
DESCRIPTION:This forum has a long-standing reputation for bringing together leading academic and industry microbiome researchers. Presentations will feature the latest research into the human microbiome as well as effective business and commercialization strategies for new products. \n \nTopics covered on the agenda include: \n\nIBD\, Colitis\, and Metabolic Diseases\nGut-brain axis\nWomen’s health\nSkin & Cosmeceuticals\nPersonalized nutrition\nBusiness Collaboration – Regulations & Investment\nProbiotics & Prebiotics\nRoundtable discussions\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/8th-microbiome-rd-business-collaboration-forum-usa/
LOCATION:San Diego\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201105
DTEND;VALUE=DATE:20201107
DTSTAMP:20260515T042424
CREATED:20200422T105422Z
LAST-MODIFIED:20200605T110713Z
UID:25195-1604534400-1604707199@www.pharmajournalist.com
SUMMARY:2nd Skin Microbiome & Cosmeceuticals Congress: USA
DESCRIPTION:This congress will explore the burgeoning field of skin microbiome research\, with case studies focused on topics such atopic dermatitis\, psoriasis\, acne\, and allergy\, and the microbiome-based products being developed to fight these diseases. The conference also provided insight into the future of microbiome-based cosmetics\, with numerous presentations given on trial design\, commercial strategy\, and consumer awareness and expectations. \nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/2nd-skin-microbiome-cosmeceuticals-congress-usa/
LOCATION:San Diego\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201105
DTEND;VALUE=DATE:20201107
DTSTAMP:20260515T042424
CREATED:20200422T133821Z
LAST-MODIFIED:20200605T111031Z
UID:25202-1604534400-1604707199@www.pharmajournalist.com
SUMMARY:5th Probiotics & Prebiotics Congress: USA
DESCRIPTION:This Congress will include numerous presentations on probiotics discovery and product development\, as well as prebiotics\, diet and nutrition. Alongside several case studies on digestive health\, metabolic diseases\, ageing and allergy\, the conference highlighted the importance of the early life microbiome\, the milk microbiome\, and the use of probiotics to modulate the infant gut. \nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda. \n 
URL:https://www.pharmajournalist.com/event/5th-probiotics-prebiotics-congress-usa/
LOCATION:San Diego\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
END:VCALENDAR